Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Role of mevalonate pathway intermediates in anticancer effect of statins


ABSTRACT: Simvastatin has been widely used for treatment of hypercholesterolemia due to its ability to inhibit HMG-CoA reductase, the rate limiting enzyme of de novo cholesterol synthesis via mevalonate pathway. Its inhibitory action causes also depletion of pathway intermediates, farnesyl pyrophosphate (FPP) and geranyl-geranyl pyrophosphate (GGPP), which are inevitable for proper targeting of small GTPases (e.g. Ras proteins) to their site of action. We profiled by array the gene expression of MIA PaCa-2 cells treated with simvastatin, FPP, GGPP and their combinations. The inhibitory effect of statins on GFP-K-Ras protein trafficking were partially prevented by addition of the mevalonate pathway intermediates. We conclude that the anticancer effect of simvastatin is to a large extent mediated through isoprenoid intermediates of the mevalonate pathway.

ORGANISM(S): Homo sapiens

SUBMITTER: Michal Kolar 

PROVIDER: E-MTAB-3263 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2024-09-08 | GSE252007 | GEO
2012-02-13 | E-GEOD-35755 | biostudies-arrayexpress
2024-09-09 | PXD048067 |
2017-12-30 | E-MTAB-3979 | biostudies-arrayexpress
2010-05-05 | E-GEOD-13424 | biostudies-arrayexpress
2023-05-01 | GSE215949 | GEO
2009-02-20 | GSE13424 | GEO
2012-02-13 | GSE35755 | GEO
2023-03-10 | GSE225681 | GEO
2022-10-03 | GSE214508 | GEO